Skip to main content
OpenTrials
Completed

NCT Number: NCT04037085

Ketamine to Improve Recovery After Cesarean Delivery - Part 1

The objective of this study is evaluate the breastmilk transfer and pharmacokinetics (Part 1) and effectiveness (Part 2) of a post-cesarean delivery intravenous ketamine bolus-and-infusion strategy, as a preventive analgesic modality to reduce pain and opioid requirements.

In Part 1, physiochemical analysis of pharmacokinetic/pharmacodynamic (PK/PD) and breastmilk transfer of ketamine and its metabolites will be assessed. Additionally calculated estimations for neonatal and infant exposure will be assessed.

In Part 2, PK/PD assessments will continue in a larger cohort; endpoints will also include postpartum pain, depression scores, central sensitization measures, patient-reported postpartum recovery scores, breastfeeding, and parent-infant bonding, assessed in the acute post-cesarean period and up to 12 weeks postpartum in a randomized controlled trial.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Obstetric Pain Acute Pain Behavior Breast Feeding Breastfeeding Chronic Pain Depression, Postpartum Depressive Disorder Drug Effect Feeding Behavior Female Urogenital Diseases and Pregnancy Complications Labor Pain Mental Disorders Mood Disorders Neurologic Manifestations Obstetric Anesthesia Problems Opioid Use Pain Pain, Acute Pain, Chronic Pathological Conditions, Signs and Symptoms Postpartum Depression Pregnancy Complications Puerperal Disorders Signs and Symptoms Urogenital Diseases

Age range

18 year–99 year

Sex eligibility

Female

Study type

Interventional

Phase

Phase 2

Primary location

Minhnoi C Wroble Biglan, Pittsburgh, Pennsylvania, United States

Loading trial locations.

About this study

Postpartum pain management strategies currently permit opioids for breakthrough pain, but strategies focused on minimizing or eliminating opioids are lacking. In the non-obstetric surgical population, modalities such as intravenous ketamine are well-recognized as effective adjuncts in opioid-reduction strategies for postoperative pain. Although there have been some studies of ketamine exposure in postpartum women without deleterious outcomes noted, these studies in pregnant and lactating women are limited by a lack of information on maternal pharmacokinetics, breastmilk secretion, and clinical effectiveness when used with standard multimodal analgesic approaches. There is also a lack of information on intermediate and long-term outcomes in this setting. This two-part trial will address these knowledge gap by advancing understanding of the safety and efficacy of ketamine and its metabolites in peripartum populations.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Adult female patients (i.e., ≥18 years of age) and able to provide informed consent
  • Cesarean Delivery, Scheduled or Non-Emergent (delivery within 15 minutes not necessary), or female weaning off of breastfeeding
  • Cesarean cohort: ASA PS 2 or 3, with or without E designation (delivery within 15 minutes not necessary), Scheduled or Non-Emergent
  • Spinal anesthesia with intrathecal morphine if Cesarean Delivery, Scheduled or Non-Emergent
  • Multimodal postop analgesia with IV ketorolac, PO NSAID, and PO APAP if Cesarean Delivery, Scheduled or Non-Emergent
  • Women who do not plan to breastfeed or who want to temporarily withhold breastfeeding or who are weaning off of breastfeeding (Part 1)

Exclusion criteria

  • Cesarean Delivery under General Anesthesia
  • Allergies to study medications
  • ASA PS 4 or 4E
  • ASA PS with E designation because delivery within 15 minutes required
  • ASA PS greater than 4 (moribund patients)
  • Contraindications to spinal anesthesia
  • Contraindications to NSAIDs (gastric bypass, etc.)
  • Contraindication to any other multimodal analgesia medicine
  • Significant psychiatric history (depression and anxiety NOT exclusion criteria), uncontrolled hyperthyroidism, cardiac disease, fever, hypertension
  • Adverse occurrence during caesarean section such as hemorrhage, need for transfusion, hemodynamic instability
  • Placenta accreta spectrum or previa with large anticipated blood loss
  • History of hallucinations, alcohol or illicit substance use/abuse, chronic opioid therapy, or chronic pain (chronic pain - defined by any condition requiring consistent follow up with pain specialist or daily administration of pain medications that could augment sedative effects)
  • Pre-eclampsia with severe features

Treatment and study plan

ketamine

Drug

Subjects in the intervention arm will receive infusion dosing as noted in arm/group descriptions at the time of cord clamping. Duration of infusion will be 12 hours. Concentrations of ketamine and ketamine metabolites (nor-ketamine, NKET; and dehydro-nor-ketamine, DHNK) are measured in maternal plasma and urine as well as breastmilk. Maternal side effects, adverse events, and efficacy endpoints will be measured over the 12 hour infusion and over 15 hours after infusion discontinuation.

Other names: Ketalar

Primary outcomes

  1. Ketamine (AUC)

    Time frame: 12 hour ketamine infusion

    Plasma will be used to calculate area under the plasma concentration-time curve (AUC 0-∞) of ketamine levels during infusion. The area under the plasma drug concentration-time curve (AUC) reflects the actual body exposure to drug after administration of a dose of the drug.

  2. Steady State (Css)

    Time frame: 12 hours after ketamine infusion start

    Ketamine steady state (Css) is defined as the concentration of drug in plasma at steady state.

  3. Elimination Half Life (T1/2) for Ketamine

    Time frame: 27 hours postpartum or 24 hour CTRC appointment for weaning population

    Postpartum maternal plasma serum will be used to calculate postpartum maternal ketamine half-life (T1/2). b. Elimination half-life (t½) is the time required for drug concentration to decrease by one-half at the end drug dosing. Elimination half-life was obtained from the slope of terminal elimination phase.

  4. Volume of Distribution Steady State (Vdss)

    Time frame: 27 hours postpartum or 24 hour CTRC appointment for weaning population

    Volume Distribution Steady State (Vdss) is the period of dynamic equilibrium of the drug calculated as the amount of drug in the body at time, t divided by the plasma concentration of the drug at time, t.

  5. Ketamine Milk to Plasma Ratio (M:P)

    Time frame: 27 hours postpartum or 24 hour CTRC appointment for weaning population

    Milk to plasma ratio for KET were calculated by dividing the concentration of the respective components Ketamine in human milk by plasma concentration at the corresponding times (± 30 min). Ratios higher than 1 indicate breastmilk concentrations of ketamine and the metabolites would be higher in breastmilk than in maternal plasma concentrations.

  6. Nor-ketamine Milk to Plasma Ratio

    Time frame: 27 hours postpartum or 24 hour CTRC appointment for weaning population

    Milk to plasma ratio of the Ketamine metabolite, Norketamine, calculated as the percentage of the maternal ketamine dose found from breastmilk. Milk to plasma ratio for NKET was calculated by dividing the concentration of the respective components Ketamine and Ketamine metabolites in human milk by plasma concentration at the corresponding times (± 30 min). Ratios higher than 1 indicate breastmilk concentrations of metabolites would be higher in breastmilk than in maternal plasma concentrations.

  7. Hydroxynorketamine M:P Ratio

    Time frame: 27 hours postpartum or 24 hour CTRC appointment for weaning population

    Milk to plasma ratio of the Ketamine metabolite, Hydroxynorketamine, calculated as the percentage of the maternal ketamine dose found from breastmilk. Milk to plasma ratio for hydroxynorketamine was calculated by dividing the concentration of the respective ketamine metabolites in human milk by plasma concentration at the corresponding times (± 30 min). Ratios higher than 1 indicate breastmilk concentrations of the metabolites would be higher in breastmilk than in maternal plasma concentrations.

  8. Relative Infant Dose of Ketamine (RID KET)

    Time frame: 27 hours postpartum or 24 hour CTRC appointment for weaning population

    Relative infant dose will be calculated as the percentage of the maternal ketamine dose found from breastmilk. The relative infant dose was calculated from the concentrations of ketamine in breast milk at different times following ketamine administration to the women. The concentration of ketamine was converted to amount by multiplying with the volume of breast milk collected at various time intervals. The cumulative dose of ketamine was calculated. An RID ≤10% was considered low.

  9. Relative Infant Dose of Ketamine Equivalent (Ketamine, Norketamine, Dehydro-norketamine)

    Time frame: 27 hours postpartum or 24 hour CTRC appointment for weaning population

    Relative infant dose (RID) will be calculated as the percentage of the maternal ketamine dose found from breastmilk. The relative infant dose was calculated from the concentrations of ketamine and its metabolites (ketamine, norketamine & dehydro-norketamine) in breast milk at different times following ketamine administration to the women.

Sponsors and collaborators

Lead sponsor

Grace Lim, MD, MS

Other

Collaborators

  • University of Pittsburgh

Registry information

Official study title

Evaluation of PK/PD, Breastmilk Transfer, and Effectiveness of Ketamine After Cesarean Delivery - Part 1

Acronym: KINETIC

Important dates

Study start
2019
Primary completion
2021
Study completion
2021
First posted
Jul 30, 2019
Registry last updated
Dec 20, 2022

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.